It contains an inhaled corticosteroid called budesonide that helps alleviate airway inflammation and a long-acting bronchodilator called formoterol fumarate dihydrate that helps keep airways open.

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) can cause side effects that range from mild to serious. If side effects from Breztri become ...

In addition, he took his controller medication therapies, including budesonide-formoterol, 160-4.5 micrograms, two puffs twice a day. Tiotropium bromide, 1.25 micrograms, two puffs daily ...

AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...

AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma.

AstraZeneca’s fixed-dose triple-combination therapy, Breztri meets primary endpoints in KALOS & LOGOS phase III trials in asthma: Cambridge, UK Saturday, May 3, 2025, 10:00 Hrs ...

AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with ...